<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919735</url>
  </required_header>
  <id_info>
    <org_study_id>ELAN</org_study_id>
    <nct_id>NCT02919735</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)</brief_title>
  <acronym>ELAN</acronym>
  <official_title>A Randomized, Double Blind, Single Center, Controlled Study to Compare the Efficacy, Safety and Tolerability of CG 428 Cutaneous Solution With Placebo on Alopecia in Cancer Female Patients Under Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Legacy Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Legacy Healthcare SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II clinical trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this trial is to compare the degree of efficacy, safety and tolerability of CG 428
      cutaneous solution versus placebo on prevention of chemotherapy induced alopecia (CIA) in
      female patients with metastatic cancer treated with selected regimens inducing alopecia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of hair loss at different time points based of on Olsen's Visual Analog Scale (OVAS) and using the Severity of Alopecia Tool score (SALT score)</measure>
    <time_frame>Every 3 to 8 weeks (variable). The following investigations will be performed every 3 to 4 weeks during the study treatment</time_frame>
    <description>Physical examination of the scalp: skin AEs, hair status (alopecia graded according to CTCAE v.4.03.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of grade 2 alopecia according to CTCAE v. 4.03.</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
    <description>CTCAE v. 4.03 : Common Toxicity Criteria for Adverse Event (skin toxicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach grade 2 alopecia during chemotherapyaccording to CTCAE v. 4.03. .</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
    <description>CTCAE v. 4.03 : Common Toxicity Criteria for Adverse Event (skin toxicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recover to grade 1 and grade 0 according to CTCAE v. 4.03 after the last dose of the selected chemotherapy</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
    <description>CTCAE v. 4.03 : Common Toxicity Criteria for Adverse Event (skin toxicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of hair loss according to OVAS (Olsen's visual analog scale) at different time points after the end of the chemotherapy.</measure>
    <time_frame>Every 3 to 8 weeks (variable). The following investigations will be performed every 3 to 4 weeks during the study treatment</time_frame>
    <description>Olsen's visual analog scale : visual aid for estimating percentage scalp hair loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events based on the CTCAE 4.03.</measure>
    <time_frame>Every 3 to 8 weeks (variable). The following investigations will be performed every 3 to 4 weeks during the study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's subjective assessment through questionnaire</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Alopecia</condition>
  <arm_group>
    <arm_group_label>CG 428 cutaneous solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herbal Medicinal Product, topical use by spray on the scalp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cutaneous solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, topical use by spray on the scalp</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG 428 cutaneous solution</intervention_name>
    <description>The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours</description>
    <arm_group_label>CG 428 cutaneous solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cutaneous solution</intervention_name>
    <description>The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours</description>
    <arm_group_label>Placebo cutaneous solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult female, age ≥ 18 years.

          -  Patient with cancer, requiring one of the following pre-specified chemotherapy regimen
             according to local guidelines: weekly paclitaxel, weekly docetaxel, eribuline or
             associationof weekly paclitaxel/docetaxel with carboplatine (association of targeted
             therapies not influencing significantly the risk of alopecia is allowed, i.e.
             trastuzumab, pertuzumab or bevacizumab).

          -  Healthy hair (no current alopecia or scalp disease treatment).

          -  Life expectancy ≥ 6 months.

          -  Able to use the study treatment in compliance with the protocol.

          -  Physical and psychological ability to participate.

          -  Negative serum pregnancy test within 14 days prior to randomization in premenopausal
             women with childbearing potential.

          -  Patients must agree to not shave their head (minimum ≥ 1 cm).

          -  Signed and dated informed consent.

        Exclusion Criteria:

          -  Other ongoing anti-neoplastic therapy or other investigational drug with potential
             effect on hair growth.

          -  Patients treated with proteasome inhibitors, i.e. bortezomib.

          -  Prior radiotherapy to the scalp with residual alopecia.

          -  Known allergy or hypersensitivity to some components of CG 428 cutaneous solution
             (including allium cepa (onion), citrus, caffeine, theobromine).

          -  Pre-existing alopecia or significant scalp disease, which may alter study treatment
             administration or absorption.

          -  Concomitant use of cold cap or any other anti-hair loss treatment.

          -  Hair transplants.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalil KZ ZAMAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Oncology - CHUV, 1011 Lausanne - CH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khalil KZ ZAMAN, PhD</last_name>
    <phone>+41 79 556 78 01</phone>
    <email>khalil.zaman@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole NJ JAMES FARESSE, PhD</last_name>
    <phone>+41 21 314 33 69</phone>
    <email>Nicole.James-Faresse@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHUV Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalil KZ ZAMAN, PhD</last_name>
      <phone>+41795567801</phone>
      <email>khalil.zaman@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Nicole NJ JAMES FARESSE, PhD</last_name>
      <phone>+41213143369</phone>
      <email>Nicole.James-Faresse@chuv.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alopecia</keyword>
  <keyword>Hair</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

